SEC Comment Letter 0000000000-23-007536 to ENZO BIOCHEM INC (ENZ) (CIK 0000316253)
ENZO BIOCHEM INC (ENZ) (CIK 0000316253)
Date: July 14, 2023 · CIK: 0000316253 · Accession: 0000000000-23-007536
AI Filing Summary & Sentiment
File numbers found in text: 333-272727
Letter
United States securities and exchange commission logo July 14, 2023 Hamid Erfanian Chief Executive Officer ENZO BIOCHEM INC 81 Executive Blvd., Suite 3 Farmingdale, New York 11735 Re:ENZO BIOCHEM INC Amendment No. 1 to Registration Statement on Form S-3 Filed July 10, 2023 File No. 333-272727 Dear Hamid Erfanian: We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our June 28, 2023 letter. Amendment No. 1 to Registration Statement on Form S-3 Cover Page 1.We note your amended disclosure in response to comments 1 and 2, including that the occurrence of an event of default, including failing to consummate the asset sale, may result in the acceleration of the your obligations under the Debentures, and if this were to occur, you may neither have sufficient cash on hand nor have access to liquidity to be able to repay such obligations, which could result in you pursuing, among other options, bankruptcy and liquidation. Please amend your disclosure to clarify the impact on equity holders if you were to file for bankruptcy, including whether equity holders could expect any recovery in bankruptcy.
FirstName LastNameHamid Erfanian Comapany NameENZO BIOCHEM INC July 14, 2023 Page 2 FirstName LastName Hamid Erfanian ENZO BIOCHEM INC July 14, 2023 Page 2 Please contact Jessica Ansart at 202-551-4511 or Katherine Bagley at 202-551-2545 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Dan Woodard
Show Raw Text
United States securities and exchange commission logo
July 14, 2023
Hamid Erfanian
Chief Executive Officer
ENZO BIOCHEM INC
81 Executive Blvd., Suite 3
Farmingdale, New York 11735
Re:ENZO BIOCHEM INC
Amendment No. 1 to Registration Statement on Form S-3
Filed July 10, 2023
File No. 333-272727
Dear Hamid Erfanian:
We have reviewed your amended registration statement and have the following
comments. In some of our comments, we may ask you to provide us with information so we
may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments. Unless we note
otherwise, our references to prior comments are to comments in our June 28, 2023 letter.
Amendment No. 1 to Registration Statement on Form S-3
Cover Page
1.We note your amended disclosure in response to comments 1 and 2, including that the
occurrence of an event of default, including failing to consummate the asset sale, may
result in the acceleration of the your obligations under the Debentures, and if this were to
occur, you may neither have sufficient cash on hand nor have access to liquidity to be able
to repay such obligations, which could result in you pursuing, among other options,
bankruptcy and liquidation. Please amend your disclosure to clarify the impact on equity
holders if you were to file for bankruptcy, including whether equity holders could expect
any recovery in bankruptcy.
FirstName LastNameHamid Erfanian
Comapany NameENZO BIOCHEM INC
July 14, 2023 Page 2
FirstName LastName
Hamid Erfanian
ENZO BIOCHEM INC
July 14, 2023
Page 2
Please contact Jessica Ansart at 202-551-4511 or Katherine Bagley at 202-551-2545 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Dan Woodard